Oncolin Therapeutics Signs Agreement with Leading Cancer Center
News Jun 12, 2008
Oncolin Therapeutics, Inc. has announced that it has signed a sponsored research agreement with The University of Texas M. D. Anderson Cancer Center (UTMDACC) in Houston, Texas to support work in the laboratory of Prof. Waldemar Priebe.
This new sponsored research will focus on the development of a new novel class of compounds that inhibit glycolysis, the metabolic pathway essential to the survival of many human tumors.
The company will have a right to an exclusive license to any new patents derived from this research as the company expands its support of Dr. Priebe’s drug discovery and development efforts.
This sponsored research will initially focus on evaluation of the selected lead compounds with the goal of identifying a superior inhibitor of glycolysis that potently blocks tumor growth.
Professor Waldemar Priebe is a world renowned scientist who has several drugs in clinical development based on research from his laboratory and works at UTMDACC, which is the world’s premier cancer center.
“Oncolin is committed to the research in Dr. Priebe’s laboratory in this important area of glycolysis inhibition for cancer treatment. This agreement expands our commitment to this area of cancer research and our goal of bringing the best drug in this therapeutic class into clinical development for patients,” said Dr Donald Picker, Chief Operating Officer of Oncolin.
Researchers say they have discovered a gene mutation that slows the metabolism of sugar in the gut, giving people who have the mutation a lower risk of diabetes, obesity, heart failure, and even death. The researchers say their finding could provide the basis for drug therapies that could mimic the workings of this gene mutation.
A computer-guided algorithm may help scientists find just the right spot to split a protein and then reassemble it to functionality, according to a new study. Researchers say this could be another step — perhaps even a dance step — toward using chemical and light signals to create new medical treatments and biosensors.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019